Mark de Caestecker
Associate Professor of Medicine
Last active: 10/23/2018

  1. Translating Knowledge Into Therapy for Acute Kidney Injury. de Caestecker M, Harris R (2018) Semin Nephrol 38(1): 88-97
    › Primary publication · 29291764 (PubMed) · PMC5894099 (PubMed Central)
  2. Overcoming Translational Barriers in Acute Kidney Injury: A Report from an NIDDK Workshop. Zuk A, Palevsky PM, Fried L, Harrell FE, Khan S, McKay DB, Devey L, Chawla L, de Caestecker M, Kaufman JS, Thompson BT, Agarwal A, Greene T, Okusa MD, Bonventre JV, Dember LM, Liu KD, Humphreys BD, Gossett D, Xie Y, Norton JM, Kimmel PL, Star RA (2018) Clin J Am Soc Nephrol 13(7): 1113-1123
    › Primary publication · 29523680 (PubMed) · PMC6032575 (PubMed Central)
  3. BMPR2 mutations and endothelial dysfunction in pulmonary arterial hypertension (2017 Grover Conference Series). Frump A, Prewitt A, de Caestecker MP (2018) Pulm Circ 8(2): 2045894018765840
    › Primary publication · 29521190 (PubMed) · PMC5912278 (PubMed Central)
  4. Drug Discovery to Halt the Progression of Acute Kidney Injury to Chronic Kidney Disease: A Case for Phenotypic Drug Discovery in Acute Kidney Injury. Hukriede N, Vogt A, de Caestecker M (2017) Nephron 137(4): 268-272
    › Primary publication · 28614822 (PubMed)
  5. Retinoic Acid Signaling Coordinates Macrophage-Dependent Injury and Repair after AKI. Chiba T, Skrypnyk NI, Skvarca LB, Penchev R, Zhang KX, Rochon ER, Fall JL, Paueksakon P, Yang H, Alford CE, Roman BL, Zhang MZ, Harris R, Hukriede NA, de Caestecker MP (2016) J Am Soc Nephrol 27(2): 495-508
    › Primary publication · 26109319 (PubMed) · PMC4731115 (PubMed Central)
  6. Reply to "Bone morphogenetic protein's contribution to pulmonary artery hypertension". King T, de Caestecker M, Lowery JW (2016) Surg Neurol Int : 91
    › Primary publication · 27857855 (PubMed) · PMC5093875 (PubMed Central)
  7. Pyridoxamine reduces postinjury fibrosis and improves functional recovery after acute kidney injury. Skrypnyk NI, Voziyan P, Yang H, de Caestecker CR, Theberge MC, Drouin M, Hudson B, Harris RC, de Caestecker MP (2016) Am J Physiol Renal Physiol 311(2): F268-77
    › Primary publication · 27194713 (PubMed) · PMC5008672 (PubMed Central)
  8. Genotype-phenotype effects of mutations on disease severity in mouse models of pulmonary hypertension. Frump AL, Datta A, Ghose S, West J, de Caestecker MP (2016) Pulm Circ 6(4): 597-607
    › Primary publication · 28090303 (PubMed) · PMC5210048 (PubMed Central)
  9. Delayed treatment with PTBA analogs reduces postinjury renal fibrosis after kidney injury. Skrypnyk NI, Sanker S, Skvarca LB, Novitskaya T, Woods C, Chiba T, Patel K, Goldberg ND, McDermott L, Vinson PN, Calcutt MW, Huryn DM, Vernetti LA, Vogt A, Hukriede NA, de Caestecker MP (2016) Am J Physiol Renal Physiol 310(8): F705-F716
    › Primary publication · 26661656 (PubMed) · PMC4835925 (PubMed Central)
  10. Correction: Deletion of Fibroblast Growth Factor Receptor 2 from the Peri-Wolffian Duct Stroma Leads to Ureteric Induction Abnormalities and Vesicoureteral Reflux. Walker KA, Sims-Lucas S, Di Giovanni VE, Schaefer C, Sunseri WM, Novitskaya T, de Caestecker MP, Chen F, Bates CM (2016) PLoS One 11(11): e0167191
    › Primary publication · 27861580 (PubMed) · PMC5115857 (PubMed Central)